Search
Esterified estrogens
go.drugbank.com/drugs/DB09381ApprovedEsterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the
Iberdomide
go.drugbank.com/drugs/DB12101Investigationaldrugs such as lenalidomide. … [L64055] Iberdomide has shown anti-tumor activity in multiple myeloma cells resistant to lenalidomide and pomalidomide, and as a CELMoD is designed to degrade Ikaros and Aiolos more potently than immunomodulatory
IMM-101
go.drugbank.com/drugs/DB15850InvestigationalIt has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over
Trioxsalen
go.drugbank.com/drugs/DB04571ApprovedWithdrawnIn research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be
Axatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigational[A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.
Nedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigational[A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary
Crovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigational[L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
AP5280
go.drugbank.com/drugs/DB05112ExperimentalAP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Ditiocarb
go.drugbank.com/drugs/DB02520InvestigationalA chelating agent that has been used to mobilize toxic metals from the tissues of man and experimental animals. It is the main metabolite of DISULFIRAM.
Tabalumab
go.drugbank.com/drugs/DB11657InvestigationalTabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.